Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Mycobacterium leprae | PROBABLE CONSERVED TRANSMEMBRANE PROTEIN | 0.0018 | 0.0406 | 0.5 |
Plasmodium falciparum | LCCL domain-containing protein | 0.0018 | 0.0406 | 0.5 |
Mycobacterium tuberculosis | Possible arabinofuranosyltransferase AftD | 0.0018 | 0.0406 | 1 |
Trypanosoma cruzi | multicopper oxidase, putative | 0.0014 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Echinococcus multilocularis | dedicator of cytokinesis protein | 0.0094 | 0.8196 | 0.812 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Trypanosoma brucei | multicopper oxidase, putative | 0.0014 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Toxoplasma gondii | F5/8 type C domain-containing protein | 0.0018 | 0.0406 | 0.5 |
Toxoplasma gondii | F5/8 type C domain-containing protein | 0.0018 | 0.0406 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Trichomonas vaginalis | beta-hexosaminidase B, putative | 0.0018 | 0.0406 | 0.5 |
Trypanosoma cruzi | multicopper oxidase, putative | 0.0014 | 0 | 0.5 |
Toxoplasma gondii | PA14 domain-containing protein | 0.0018 | 0.0406 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Plasmodium vivax | LCCL domain-containing protein | 0.0018 | 0.0406 | 0.5 |
Plasmodium vivax | LCCL domain-containing protein | 0.0018 | 0.0406 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Mycobacterium ulcerans | oxidase | 0.0017 | 0.0368 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.0018 | 0.0406 | 0.5 |
Trichomonas vaginalis | hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0014 | 0 | 0.5 |
Onchocerca volvulus | 0.0018 | 0.0406 | 0.5 | |
Brugia malayi | Protein kinase domain containing protein | 0.0018 | 0.0406 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0014 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Onchocerca volvulus | 0.0018 | 0.0406 | 0.5 | |
Plasmodium falciparum | LCCL domain-containing protein | 0.0018 | 0.0406 | 0.5 |
Toxoplasma gondii | F5/8 type C domain-containing protein | 0.0018 | 0.0406 | 0.5 |
Echinococcus multilocularis | Coagulation factor 5 8 type, C terminal | 0.0112 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Trichomonas vaginalis | alpha-L-fucosidase, putative | 0.0018 | 0.0406 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Schistosoma mansoni | dock | 0.0112 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0018 | 0.0406 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 0 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 0.28 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 0.77 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 1.47 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 4 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 39 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition (functional) | = 88 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 4.26 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = -1 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 4 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 39 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 88 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
XC50 (functional) | = 5.95 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 1.13122 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.